Table 4.
Differentiation status in PD-1+ and PD-1- CD8+ T cells.
| RT plus camrelizumab group | CCRT group | ||||||
|---|---|---|---|---|---|---|---|
| Before treatment | During treatment | P value | Before treatment | During treatment | P value | ||
| PD-1+CD8+ T cells (%) | |||||||
| Naive | 2.92 (1.90, 3.94) |
1.41 (0.83, 1.98) |
<0.001 | 2.51 (1.79, 3.23) |
2.74 (1.49, 3.98) |
0.89 | |
| Tcm | 21.50 (17.08, 25.93) |
34.83 (28.33, 41.33) |
<0.001 | 22.52 (13.18, 31.86) |
20.47 (16.06, 24.87) |
0.64 | |
| Tem | 61.76 (55.13, 68.38) |
56.78 (49.63, 63.93) |
0.10 | 59.38 (50.16, 68.60) |
60.95 (53.62, 68.27) |
0.76 | |
| TEMRA | 13.83 (6.83, 20.83) |
6.98 (0.27, 13.70) |
<0.001 | 15.61 (9.17, 22.04) |
15.87 (10.52, 21.22) |
0.90 | |
| PD-1-CD8+ T cells (%) | |||||||
| Naive | 23.08 (15.84, 30.31) |
12.80 (8.17, 17.43) |
<0.001 | 16.93 (11.37, 22.49) |
16.65 (9.03, 24.27) |
0.85 | |
| Tcm | 12.95 (9.16, 16.74) |
15.06 (11.77, 18.34) |
0.16 | 12.39 (7.54, 17.24) |
18.84 (12.85, 24.84) |
<0.01 | |
| Tem | 38.73 (28.83, 48.63) |
52.13 (43.63, 60.64) |
<0.001 | 34.32 (26.47, 42.16) |
34.51 (26.97, 42.05) |
0.93 | |
| TEMRA | 25.26 (17.79, 32.74) |
20.01 (13.34, 26.68) |
0.02 | 36.35 (26.56, 46.15) |
30.00 (20.97, 39.03) |
0.03 | |
Paired data available at baseline and on-treatment were included. Date was shown as mean (lower 95% CI of mean, upper 95% CI of mean).